← Leaderboards
Jenna Geddes Sweeney
Harvard Medical School
$111,644
Attributed
$111,644
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $42.2K · FY2012–15$50K$37.5K$25K$12.5K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$111,644 · 1
By mechanism
F31$111,644 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Suzanne L. Walker$40,048,648
- Cassandra Marie Joiner$447,578
- Michael Springer$2,710,057
- Sara Evelyn Schwanger Martin$111,960
- Rodrigo Fermin Ortiz-Meoz$101,404
Others in their field
Top investigators on “Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
AdjuvantAdoptive ImmunotherapyAffectAffinityAnti-Cancer TherapeuticAntigensApoptosisApoptoticAttenuatedAutologousBinding (Molecular Function)Carbohydrate Binding ProteinCarbohydratesCd4 Positive T LymphocytesCd8b1 GeneCell AdhesionCell DeathCell Death InductionCell PhysiologyCellsCell SurvivalCytokineCytotoxicAcetylglucosamine
Grant awards (3)
Analyzing the Efficacy of Galectin-1 Ligand Inhibition in Adoptive T cell Therapy$35,046
F31 · FY2015 · CA · contact PI
Analyzing the Efficacy of Galectin-1 Ligand Inhibition in Adoptive T cell Therapy$34,366
F31 · FY2014 · CA · contact PI
Analyzing the Efficacy of Galectin-1 Ligand Inhibition in Adoptive T cell Therapy$42,232
F31 · FY2012 · CA · contact PI